Anti-viral DC/NK interactions
Anti-viral DC/NK interactions
批准号:
7867942
负责人:
CHRISTIAN MUNZ
金额:
$18.24万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2013-05-31
关键词:
Activated Natural Killer CellAcuteAdultAffectAnimal ModelAutoimmune DiseasesAutoimmunityB-LymphocytesBloodCD34 geneCell CommunicationCell physiologyCellsCytolysisDataDendritic CellsDendritic cell activationDeveloped CountriesDevelopmentDiseaseDouble-Stranded RNAEBV-associated malignancyEpithelialEpstein-Barr Virus InfectionsEventExposure toFailureFrequenciesHodgkin DiseaseHumanHuman Herpesvirus 4ImmuneImmune responseImmune systemIn VitroIndividualInfectionInfectious MononucleosisInfusion proceduresKnowledgeLifeLigandsLymphoidMalignant NeoplasmsMediatingModelingMusNK Cell ActivationNasopharynx CarcinomaNatural ImmunityNatural Killer CellsNeonatalOncogenicOrganPlayPoly I-CPopulationPredispositionPreparationProductionRoleSiteStem cellsSynapsesT cell responseT-LymphocyteTonsilTranslatingVaccinatedViralViremiaVirusVirus Diseasesbasecell preparationcell transformationcell typecytokinecytotoxicitydesignimmunological synapse formationin vivoin vivo Modelinterestlatent infectionlymph nodespreventpublic health relevancereceptorreconstitutionsynaptogenesistumorvaccination strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Humans harbor a substantial Natural Killer (NK) cell compartment in their secondary lymphoid organs. These NK cells are enriched for immunoregulatory CD56brightCD16- cells, which are preferentially activated by dendritic cells (DCs). Our preliminary data demonstrate that NK cell activation by DCs restricts B cell transformation by the Epstein Barr virus (EBV) in vitro, especially when the NK cells are derived from tonsils, the secondary lymphoid organ of primary EBV infection. EBV is a human tumorvirus, which establishes latent infection in more than 90% of the human adult population. It causes tumors of epithelial and B cell origin in immune competent, and at increased frequencies in immune compromised individuals. The characterization of innate immunity to EBV is of particular interest, because failure of this initial immune control might result in increased viral titers and massive T cell expansion during primary immune responses, resulting in infectious mononucleosis. In order to characterize the role of DC/NK cell interactions during EBV infections, we plan to: 1. Characterize innate NK cell activation during EBV infection. We will dissect DC/NK cell synapse formation, DC activation by EBV derived dsRNA, and tonsillar DC subsets for their activation by EBV. 2. Analyze the protective effector functions of tonsillar NK cells. We will focus on cytokine production, cytotoxicity and assistance in protective T cell polarization by NK cells after DC activation via EBV infection. 3. Investigate EBV infection in vivo. In order to translate our in vitro findings into an in vivo model of primary EBV infection, we have reconstituted human immune systems in immune compromised mice, which could mount primary protective immune responses against EBV. This model will be explored to investigate NK cell expansion and activation during primary EBV infection, the contribution of NK cells to innate immune control of EBV, and their assistance in T cell polarization of adaptive immune control of EBV. These studies will characterize the mechanisms of NK cell activation by DCs, and protective NK cell functions against B cell transformation by oncogenic EBV in vitro and in vivo. Knowledge of the establishment of protective EBV specific immune control might suggest vaccination strategies against common EBV associated tumors like nasopharyngeal carcinoma and Hodgkin's lymphoma. PUBLIC HEALTH RELEVANCE: Epstein Barr virus (EBV) causes tumors of epithelial and B cell origin in the human population, like Hodgkin's lymphoma and nasopharyngeal carcinoma. This proposal plans to investigate how two cell types of the innate immune system, dendritic cells and Natural Killer cells, interact to initially control EBV and influence other immune cells to establish life-long protection from the development of EBV associated malignancies. An understanding of these initial events during the establishment of EBV specific immune control will help us explain why some individuals develop symptomatic acute infection with EBV, called infectious mononucleosis, and identify immune compartments that should be harnessed to efficiently vaccinate against EBV associated tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Endogenous MHC class II antigen processing via autophagy
-
批准号:7124970
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2006
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Endogenous MHC class II antigen processing via autophagy
-
批准号:7252484
-
项目类别:
-
资助金额:$29.13万
-
财政年份:2006
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Endogenous MHC class II antigen processing via autophagy
-
批准号:7459601
-
项目类别:
-
资助金额:$12.43万
-
财政年份:2006
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Endogenous MHC class II antigen processing via autophagy
-
批准号:7739310
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2006
-
负责人:CHRISTIAN MUNZ
-
依托单位:
DC/NK INTERACTIONS IN HUMAN SECONDARY LYMPHOID ORGANS
-
批准号:7207031
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2005
-
负责人:CHRISTIAN MUNZ
-
依托单位:
ENDOGENOUS MHC CLASS II PROCESSING OF EBV ANTIGENS AND IMMUNE CONTROL
-
批准号:7207009
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2005
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Anti-viral DC/NK interactions
-
批准号:8132389
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
DC/NK interactions in human secondary lymphoid organs
-
批准号:6914367
-
项目类别:
-
资助金额:$27.72万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Anti-viral DC/NK interactions
-
批准号:7523776
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Anti-viral DC/NK interactions
-
批准号:8290038
-
项目类别:
-
资助金额:$17.7万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
DC/NK interactions in human secondary lymphoid organs
-
批准号:7087064
-
项目类别:
-
资助金额:$27.06万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
DC/NK interactions in human secondary lymphoid organs
-
批准号:6803661
-
项目类别:
-
资助金额:$27.63万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Anti-viral DC/NK interactions
-
批准号:7736499
-
项目类别:
-
资助金额:$15.23万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
Anti-viral DC/NK interactions
-
批准号:7647187
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2004
-
负责人:CHRISTIAN MUNZ
-
依托单位:
MHC class II processing of EBV antigens & immune control
-
批准号:7041507
-
项目类别:
-
资助金额:$0.63万
-
财政年份:2003
-
负责人:CHRISTIAN MUNZ
-
依托单位:
海外基金